DOCSLIB.ORG

COVID-19: the Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19: the Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation cells Review COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation Jihang Yu 1 , Edouard I. Azzam 1, Ashok B. Jadhav 1 and Yi Wang 1,2,* 1 Radiobiology and Health, Isotopes, Radiobiology & Environment Directorate (IRED), Canadian Nuclear Laboratories (CNL), Chalk River, ON K0J 1J0, Canada; [email protected] (J.Y.); [email protected] (E.I.A.); [email protected] (A.B.J.) 2 Department of Biochemistry Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada * Correspondence: [email protected]; Tel.: +1-613-584-3311 (ext. 42653) Abstract: The year 2020 will be carved in the history books—with the proliferation of COVID-19 over the globe and with frontline health workers and basic scientists worldwide diligently fighting to alleviate life-threatening symptoms and curb the spread of the disease. Behind the shocking prevalence of death are countless families who lost loved ones. To these families and to humanity as a whole, the tallies are not irrelevant digits, but a motivation to develop effective strategies to save lives. However, at the onset of the pandemic, not many therapeutic choices were available besides supportive oxygen, anti-inflammatory dexamethasone, and antiviral remdesivir. Low-dose radiation (LDR), at a much lower dosage than applied in cancer treatment, re-emerged after a Citation: Yu, J.; Azzam, E.I.; Jadhav, 75-year silence in its use in unresolved pneumonia, as a scientific interest with surprising effects in A.B.; Wang, Y. COVID-19: The soothing the cytokine storm and other symptoms in severe COVID-19 patients. Here, we review Disease, the Immunological the epidemiology, symptoms, immunological alterations, mutations, pharmaceuticals, and vaccine Challenges, the Treatment with development of COVID-19, summarizing the history of X-ray irradiation in non-COVID diseases Pharmaceuticals and Low-Dose (especially pneumonia) and the currently registered clinical trials that apply LDR in treating COVID- Ionizing Radiation. Cells 2021, 10, 19 patients. We discuss concerns, advantages, and disadvantages of LDR treatment and potential 2212. https://doi.org/10.3390/ avenues that may provide empirical evidence supporting its potential use in defending against cells10092212 the pandemic. Academic Editors: Serge Candéias and Katalin Lumniczky Keywords: COVID-19; SARS-CoV-2; low-dose radiotherapy; X-ray Received: 27 July 2021 Accepted: 23 August 2021 Published: 27 August 2021 1. Introduction Humans have been living in a world affected by the novel coronavirus disease (COVID- Publisher’s Note: MDPI stays neutral 19) for more than a year. Starting from a small group of infections, the highly infectious with regard to jurisdictional claims in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral strain has caused over published maps and institutional affil- 213 million reported infections, leading to ~4.46 million deaths so far [1]. Among the closed iations. cases that had an outcome of either recovery and discharge or death, the case fatality rate is ~2% [1]. Although it has been argued that social measures have been largely ineffective [2], without the assistance of non-pharmaceutical interventions such as stay-at-home, use of sanitizers (hand washing), early case detection, and face masking, it is unlikely that the size Copyright: © 2021 by the authors. of the outbreak can be mitigated or reduced [3]. Whereas active cases temporally declined Licensee MDPI, Basel, Switzerland. in February and June 2021, they have rapidly risen again reaching an even higher record This article is an open access article set in late April, and reaching over 744,000 daily new cases as of 19 August 2021 (among distributed under the terms and infected patients, 0.6% being in serious conditions) [1]. conditions of the Creative Commons As an infectious disease, COVID-19 can be transmitted from human to human through Attribution (CC BY) license (https:// respiratory droplets and aerosols created within a short distance, as well as prolonged creativecommons.org/licenses/by/ interaction [4]. The World Health Organization (WHO) presented the “three Cs” as places 4.0/). Cells 2021, 10, 2212. https://doi.org/10.3390/cells10092212 https://www.mdpi.com/journal/cells Cells 2021, 10, x FOR PEER REVIEW 2 of 28 As an infectious disease, COVID-19 can be transmitted from human to human through respiratory droplets and aerosols created within a short distance, as well as pro- longed interaction [4]. The World Health Organization (WHO) presented the “three Cs” Cells 2021, 10, 2212 as places with higher COVID-19 spreading risk: Crowded places with many2 people of 28 nearby, close-contact settings, where close-range conversations take place, and con- fined/enclosed spaces with poor ventilation [5]. These places include restaurants, bars, fitnesswith higherfacilities, COVID-19 theaters, spreading and museums risk: Crowded where people places tend with to many be crowded people nearby, and less close- fresh aircontact is available settings,. Thus, where social close-range distancing conversations (at least take 2 m place, apart and and confined/enclosed less than 30-min spaces of close contact)with poor has ventilation been advocated [5]. These as a places measure include to reduce restaurants, cluster bars, transmission fitness facilities, [6]. theaters, andSimilar museums to wherethe seasonal people flu, tend COVID to be crowded-19 is a andviral, less respiratory fresh air is illness. available. Whereas Thus, social the flu resultsdistancing from (at an least influenza 2 m apart virus and infection less than, 30-minCOVID of-19 close is caused contact) by has a new been type advocated of corona- as virusa measure—SARS to-CoV reduce-2 [7,8] cluster. SARS transmission-CoV-2 is [ 6one]. of the seven pathogenic coronaviruses that cause Similarhuman toresp theiratory seasonal diseases, flu, COVID-19 which also is a viral,include respiratory SARS-CoV, illness. MERS Whereas-CoV the(Middle flu - Eastresults respiratory from an influenzasyndrome virus coronavirus infection,) COVID-19, HCoV-OC43 is caused (human by a coronavirus new type of coronavirus— OC43), HCoV- HKU1SARS-CoV-2 (human [ 7coronavirus,8]. SARS-CoV-2 HKU1) is one, HCoV of the-NL63 seven (human pathogenic coronavirus coronaviruses NL63) that, and cause HCoV- 229Ehuman (human respiratory coronavirus diseases, 229E) which [9]. also include SARS-CoV, MERS-CoV (Middle-East respiratory syndrome coronavirus), HCoV-OC43 (human coronavirus OC43), HCoV-HKU1 2.(human Epidemiology coronavirus of COVID HKU1),-19 HCoV-NL63 (human coronavirus NL63), and HCoV-229E (human coronavirus 229E) [9]. Although the mortality data of COVID-19 are always compared with those of the flu as2. both Epidemiology induce severe of COVID-19 respiratory symptoms that can lead to death, caution must be exer- cised whenAlthough interpreting the mortality incidence data of. The COVID-19 Center for are Disease always comparedControl (CDC) withthose in the of United the Statesflu as of both America induce (USA) severe estimates respiratory the symptomsseasonal influenza that can leadmortality to death, to be caution at ~0.1% must over be the pastexercised years when[10]. In interpreting contrast to incidence. indirect Thecounting Center as for in Disease the case Control of the (CDC) flu, the in CDC the United collects eachStates COVID of America-19-related (USA) death estimates report the directly. seasonal Hence, influenza researchers mortality suggested to be at ~0.1% that overa com- parisonthe past between years [10 the]. Inweekly contrast deaths to indirect due to countingCOVID-19 as inor thethe caseflu could of the be flu, a themore CDC valid methodcollects [11] each. For COVID-19-related example, in the death USA report, the directly.weekly Hence,flu deaths researchers were around suggested 500 thatin early a 2020comparison and decrease betweend at the a weeklylater time deaths in duethe toyear COVID-19, whereas or the the fluweekly could COVID be a more-19 valid deaths soaredmethod to [over11]. For 16,000 example, and fluctuated in the USA, with the weeklytime (Figure flu deaths 1) [12] were. This around fluctuation 500 in early may 2020 result fromand a decreased shortageat of a ventilators later time in and the limit year,ations whereas associated the weekly with COVID-19 the work deaths of health soared provid- to over 16,000 and fluctuated with time (Figure1)[ 12]. This fluctuation may result from a ers. shortage of ventilators and limitations associated with the work of health providers. Figure 1. Weekly death analysis of COVID-19 and influenza in the USA. Data may lag by an Figure 1. Weekly death analysis of COVID-19 and influenza in the USA. Data may lag by an aver- average of 1–2 weeks, so the trend of decline in recent weeks may not accurately reflect the current age of 1–2 weeks, so the trend of decline in recent weeks may not accurately reflect the current situation. Available online: https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by- situation. Available online: https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by- Week-Ending-D/r8kw-7aab (accessed on 24 August 2021). Week-Ending-D/r8kw-7aab (accessed on 24 August 2021). Several situations complicate the statistics and treatment of COVID-19, including co-infectionSeveral situations with SARS-CoV-2 complicate and the commonstatistics fluand virus treatment simultaneously, of COVID or-19 infection, including with co- infectionSARS-CoV-2 with itself SARS rendering-CoV-2 and existing the diseasescommon to flu deteriorate virus simultaneously, further and causing or infection death [13 with]. Although asthma was associated with severe diseases during past influenza epidemics, and respiratory viruses were recognized as cause of acute exacerbations of asthma, sci- entific analyses did not correlate asthma with a higher severity or mortality in cases of Cells 2021, 10, 2212 3 of 28 COVID-19 [14]. As of early 2021, scientists still could not draw definitive conclusions on the correlation between asthma and COVID-19 outcomes due to various potential bias factors [15,16].
Load more

Recommended publications
  • Nucleotide Base Coding and Am1ino Acid Replacemients in Proteins* by Emil L
    VOL. 48, 1962 BIOCHEMISTRY: E. L. SAIITH 677 18 Britten, R. J., and R. B. Roberts, Science, 131, 32 (1960). '9 Crestfield, A. M., K. C. Smith, and F. WV. Allen, J. Biol. Chem., 216, 185 (1955). 20 Gamow, G., Nature, 173, 318 (1954). 21 Brenner, S., these PROCEEDINGS, 43, 687 (1957). 22 Nirenberg, M. WV., J. H. Matthaei, and 0. WV. Jones, unpublished data. 23 Crick, F. H. C., L. Barnett, S. Brenner, and R. J. Watts-Tobin, Nature, 192, 1227 (1961). 24 Levene, P. A., and R. S. Tipson, J. Biol. Ch-nn., 111, 313 (1935). 25 Gierer, A., and K. W. Mundry, Nature, 182, 1437 (1958). 2' Tsugita, A., and H. Fraenkel-Conrat, J. Mllot. Biol., in press. 27 Tsugita, A., and H. Fraenkel-Conrat, personal communication. 28 Wittmann, H. G., Naturwissenschaften, 48, 729 (1961). 29 Freese, E., in Structure and Function of Genetic Elements, Brookhaven Symposia in Biology, no. 12 (1959), p. 63. NUCLEOTIDE BASE CODING AND AM1INO ACID REPLACEMIENTS IN PROTEINS* BY EMIL L. SMITHt LABORATORY FOR STUDY OF HEREDITARY AND METABOLIC DISORDERS AND THE DEPARTMENTS OF BIOLOGICAL CHEMISTRY AND MEDICINE, UNIVERSITY OF UTAH COLLEGE OF MEDICINE Communicated by Severo Ochoa, February 14, 1962 The problem of which bases of messenger or template RNA' specify the coding of amino acids in proteins has been largely elucidated by the use of synthetic polyri- bonucleotides.2-7 For these triplet nucleotide compositions (Table 1), it is of in- terest to examine some of the presently known cases of amino acid substitutions in polypeptides or proteins of known structure.
    [Show full text]
  • Evolutionary and Functional Lessons from Human-Specific Amino-Acid
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.09.086009; this version posted May 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Evolutionary and Functional Lessons from Human-Specific Amino- Acid Substitution Matrices Tair Shauli1, Nadav Brandes1, Michal Linial 2 1The Rachel and Selim Benin School of Computer Science and Engineering, 2Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel Corresponding Author: Michal Linial Email: [email protected] ORCID: (M.L.) 0000-0002-9357-4526 Abstract The characterization of human genetic variation in coding regions is fundamental to our understanding of protein function, structure, and evolution. Amino-acid (AA) substitution matrices such as BLOSUM (BLOcks SUbstitution Matrix) and PAM (Point Accepted Mutations) encapsulate the stochastic nature of such proteomic variation and are used in studying protein families and evolutionary processes. However, these matrices were constructed from protein sequences spanning long evolutionary distances and are not designed to reflect polymorphism within species. To accurately represent proteomic variation within the human population, we constructed a set of human-centric substitution matrices derived from genetic variations by analyzing the frequencies of >4.8M single nucleotide variants (SNVs). These human-specific matrices expose short-term evolutionary trends at both codon and AA resolution and therefore present an evolutionary perspective that differs from that implicated in the traditional matrices. Specifically, our matrices consider the directionality of variants, and uncover a set of AA pairs that exhibit a strong tendency to substitute in a specific direction.
    [Show full text]
  • Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease
    molecules Review Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease Olujide O. Olubiyi 1,2,* , Maryam O. Olagunju 1 and Birgit Strodel 1,3 1 Institute of Complex Systems: Structural Biochemistry, Forschungszentrum Jülich, 52425 Jülich, Germany; [email protected] (M.O.O.); [email protected] (B.S.) 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife 220282, Nigeria 3 Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany * Correspondence: [email protected] Academic Editor: Rainer Riedl Received: 30 September 2019; Accepted: 9 December 2019; Published: 12 December 2019 Abstract: Sickle cell disease (SCD) is a group of inherited disorders affecting red blood cells, which is caused by a single mutation that results in substitution of the amino acid valine for glutamic acid in the sixth position of the β-globin chain of hemoglobin. These mutant hemoglobin molecules, called hemoglobin S, can polymerize upon deoxygenation, causing erythrocytes to adopt a sickled form and to suffer hemolysis and vaso-occlusion. Until recently, only two drug therapies for SCD, which do not even fully address the manifestations of SCD, were approved by the United States (US) Food and Drug Administration. A third treatment was newly approved, while a monoclonal antibody preventing vaso-occlusive crises is also now available. The complex nature of SCD manifestations provides multiple critical points where drug discovery efforts can be and have been directed. These notwithstanding, the need for new therapeutic approaches remains high and one of the recent efforts includes developments aimed at inhibiting the polymerization of hemoglobin S.
    [Show full text]
  • Synthetic Polynucleotides Andthe Amino Acid
    VOL. 48, 1962 BIOCHEMISTRY: SPEYER ET AL. 63 14 Meselson, M., F. W. Stahl, and J. Vinograd, these PROCEEDINGS, 43, 581 (1957). 15 Szybalski, W., Experientia, 16, 164 (1960). 16 Zubay, G., Nature, 182, 1290 (1958); Stent, G., Adv. in Virus Res., 5, 95 (1958); Sinsheimer, R. L., J. Mol. Biol., 1, 218 (1959); Rich, A., Ann. N. Y. Acad. Sci., 81, 709 (1959). 17 Zalokar, M., Exp. Cell Res., 19, 559 (1960). SYNTHETIC POLYNUCLEOTIDES AND THE AMINO ACID CODE, I* BY JOSEPH F. SPEYER, PETER LENGYEL, CARLOS BASILIO, t AND SEVERO OCHOA DEPARTMENT OF BIOCHEMISTRY, NEW YORK UNIVERSITY SCHOOL OF MEDICINE Communicated November 21, 1961 Previous studies' on the incorporation of amino acids into acid-insoluble products by an Escherchia coli system, in the presence of synthetic polyribonucleotides, have been continued. This paper presents additional results with previously used and new copolymers containing uridylic2 and guanylic acid (UG); uridylic, adenylic, and cytidylic acid (UAC); uridylic, cytidylic, and guanylic acid (UCG); and uridy- lic, adenylic, and guanylic acid (UAG). Assuming a triplet code, code letters (although in an as yet unspecified sequence) can now be assigned to the following eleven amino acids: cysteine, histidine, isoleucine, leucine, lysine, phenylalanine, proline, serine, threonine, tyrosine, and valine. Preparations and Methods.-These were as previously described.' The following new polymers were prepared with polynucleotide phosphorylase. Poly UC (3: 1), from a mixture of UDP and CDP in molar ratio 3:1; poly UG (5:1), from UDP and GDP in molar ratio 5:1; poly UAC, from UDP, ADP, and CDP in molar ratio 6:1: 1; poly UCG and poly UAG, from mixtures of the appropriate nucleoside 5'-diphosphates in molar ratio of 6 of UDP to 1 of each of the other two.
    [Show full text]
  • Nucleotide Base Coding and Am1ino Acid Replacemients in Proteins* by Emil L
    VOL. 48, 1962 BIOCHEMISTRY: E. L. SAIITH 677 18 Britten, R. J., and R. B. Roberts, Science, 131, 32 (1960). '9 Crestfield, A. M., K. C. Smith, and F. WV. Allen, J. Biol. Chem., 216, 185 (1955). 20 Gamow, G., Nature, 173, 318 (1954). 21 Brenner, S., these PROCEEDINGS, 43, 687 (1957). 22 Nirenberg, M. WV., J. H. Matthaei, and 0. WV. Jones, unpublished data. 23 Crick, F. H. C., L. Barnett, S. Brenner, and R. J. Watts-Tobin, Nature, 192, 1227 (1961). 24 Levene, P. A., and R. S. Tipson, J. Biol. Ch-nn., 111, 313 (1935). 25 Gierer, A., and K. W. Mundry, Nature, 182, 1437 (1958). 2' Tsugita, A., and H. Fraenkel-Conrat, J. Mllot. Biol., in press. 27 Tsugita, A., and H. Fraenkel-Conrat, personal communication. 28 Wittmann, H. G., Naturwissenschaften, 48, 729 (1961). 29 Freese, E., in Structure and Function of Genetic Elements, Brookhaven Symposia in Biology, no. 12 (1959), p. 63. NUCLEOTIDE BASE CODING AND AM1INO ACID REPLACEMIENTS IN PROTEINS* BY EMIL L. SMITHt LABORATORY FOR STUDY OF HEREDITARY AND METABOLIC DISORDERS AND THE DEPARTMENTS OF BIOLOGICAL CHEMISTRY AND MEDICINE, UNIVERSITY OF UTAH COLLEGE OF MEDICINE Communicated by Severo Ochoa, February 14, 1962 The problem of which bases of messenger or template RNA' specify the coding of amino acids in proteins has been largely elucidated by the use of synthetic polyri- bonucleotides.2-7 For these triplet nucleotide compositions (Table 1), it is of in- terest to examine some of the presently known cases of amino acid substitutions in polypeptides or proteins of known structure.
    [Show full text]
  • Beyond Mistranslation: Expanding the Role of Aminoacyl-Trna Synthetases Towards the Maintenance of Cellular Viability DISSERTATI
    Beyond Mistranslation: Expanding the Role of Aminoacyl-tRNA Synthetases towards the Maintenance of Cellular Viability DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Kyle Phillip Mohler Graduate Program in Microbiology The Ohio State University 2017 Dissertation Committee: Professor Michael Ibba, Advisor Professor Juan Alfonzo Professor Irina Artsimovitch Professor Kelly Wrighton Copyrighted by Kyle Phillip Mohler 2017 Abstract When the sequence of amino acids in a newly synthesized protein is not the same as the genetically encoded sequence, a gene is said to have been mistranslated. Alterations in protein sequence resulting from errors in genome maintenance and expression occur with low frequency. The next step in gene expression, protein synthesis, offers the greatest opportunity for errors, with mistranslation events routinely occurring at a frequency of ~1 per 10,000 mRNA codons translated. The translation of genetic information into functional proteins is a multistep process. Aminoacyl-tRNA synthetases (aaRSs) provide the cell with substrates for protein synthesis by correctly pairing amino acids with their cognate tRNAs. Aminoacylation occurs in a two-step reaction. First, cognate amino acid is activated within the catalytic domain to form an aminoacyl-adenylate (aa-AMP). The activated amino acid is then transferred to the 3’ OH of the terminal adenosine on the tRNA acceptor stem of its cognate tRNA, forming an aminoacyl-tRNA (aa-tRNA). Phenylalanyl-tRNA synthetase (PheRS), for example, is responsible for pairing phenylalanine (Phe) with tRNAPhe. Mispaired aa-tRNA species occasionally arise due to a lack of adequate amino acid discrimination within the PheRS active site, resulting in the synthesis of misacylated Tyr- tRNAPhe.
    [Show full text]
  • Investigation of Mutations in Nuclear Genes That Affect the Atp Synthase Russell Dsouza Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2016 Investigation Of Mutations In Nuclear Genes That Affect The Atp Synthase Russell Dsouza Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Biochemistry Commons, and the Molecular Biology Commons Recommended Citation Dsouza, Russell, "Investigation Of Mutations In Nuclear Genes That Affect The tA p Synthase" (2016). Wayne State University Dissertations. 1526. https://digitalcommons.wayne.edu/oa_dissertations/1526 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. INVESTIGATION OF MUTATIONS IN NUCLEAR GENES THAT AFFECT THE ATP SYNTHASE by RUSSELL L. D’SOUZA DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2016 MAJOR: BIOCHEMISTRY & MOLECULAR BIOLOGY Approved By: Advisor Date © COPYRIGHT BY RUSSELL L. D’SOUZA 2016 All Rights Reserved DEDICATION I dedicate my dissertation work to my family. My deepest gratitude to my parents, Raymond and Emma D’Souza, whose constant support has helped me pursue my dreams. My brother Reuben, who has always been there by my side. I also dedicate this thesis to my wife, Jayshree Bhakta, who has always been there for me during the difficult times at graduate school. I will always appreciate all that she’s done for me and for all the encouragement. She’s been the best cheerleader in my life. Finally, a special thanks to my best friend Joe D.
    [Show full text]
  • Of the Same Glycine Residue by Arginine and Glutamic Acid Residues
    VOL. 48, 1962 GENETICS: HENNING AND YANOFSKY 1497 of their data with ours indicates that the phenomenon described herein is most likely due to the combination of ma-i + and ry+ subunits. We have also observed reactivation of "inactive" xanthine dehydrogenase of wild-type Drosophila. II Forrest, H. S., E. W. Hanly, and J. M. Lagowski, Genetics, 56, 1455 (1961). 12Horowitz, N., personal communication. 13 Hadorn, E., and I. Schwink, Nature, 177, 940 (1956); Glassman, E., Dros. Inform. Service, 31, 121 (1957). '4Glassman, E., and W. Pinkerton, Science, 131, 1810 (1960). AMINO ACID REPLACEMENTS ASSOCIATED WITH REVERSION AND RECOMBINA TION WITHIN THE A GENE* BY ULF HENNINGt AND CHARLES YANOFSKY DEPARTMENT OF BIOLOGICAL SCIENCES, STANFORD UNIVERSITY, STANFORD, CALIFORNIA Communicated by V. C. Twitty, July 26, 1962 Studies with the A protein of the tryptophan synthetase of Escherichia coli have established that mutationally altered sites that are located at or near the same position in the A gene lead to amino acid substitutions in the same tryptic peptide of the A protein." 2 It has also been shown that two mutants, strains A23 and A46, with alterations extremely close to one another on the genetic map, form A proteins that are distinguishable from the wild-type A protein by the replacement of the same glycine residue by arginine and glutamic acid residues, respectively.1 2 It was concluded from these findings that the mutational alteration characteristic of each of the mutants involved a different nucleotide in the same amino acid coding unit in the A gene. 1 2 Mutants A23 and A46 revert spontaneously to tryptophan independence.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,338,790 B2 Thierbach Et Al
    US007338790B2 (12) United States Patent (10) Patent No.: US 7,338,790 B2 Thierbach et al. (45) Date of Patent: Mar. 4, 2008 (54) ALLELES OF THE GND GENE FROM 2004/0063181 A1 4/2004 Duncan et al. CORYNEFORM BACTERIA 2006, O246554 A1 11/2006 Thierbach et al. (75) Inventors: Georg Thierbach, Bielefeld (DE): Brigitte Bathe, Salzkotten (DE); Natalie Schischka, Bielefeld (DE) FOREIGN PATENT DOCUMENTS (73) Assignee: Degussa AG, Intellectual Property EP 1 462516 A1 9, 2004 Management, Hanau (DE) WO WOO 1/71012 A1 9, 2001 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 11/227,138 Yousuke Nishio, et al., “Comparative Complete Genome Sequence Analysis of the Amino Acid Replacements Responsible for the (22) Filed: Sep. 16, 2005 Thermostability of Corynebacterium efficiens”. Genome Research, XP-002995065, 2003, pp. 1572-1579 and 2 pages of DATABASE (65) Prior Publication Data UniProt, AN Q8FTI1, XP-002375536, Mar. 1, 2003. US 2006/0246554 A1 Nov. 2, 2006 A. M. Cerdeno-Tarraga, et al., “The complete genome sequence and analysis of Corynebacterium diphteriae NCTC 13129. Nucleic Related U.S. Application Data Acids Research, vol. 31, No. 22, XP-002375534, Nov. 15, 2003, pp. 6516-6523 and 2 pages of DATABASE UniProt, AN Q6NHC5, (60) Provisional application No. 60/646,482, filed on Jan. XP-002375537, Jul. 5, 2004. 25, 2005. U.S. Appl. No. 1 1/227,138, filed Sep. 16, 2005, Thierbach et al. (30) Foreign Application Priority Data U.S.
    [Show full text]
  • Incorporating Nonproteinogenic Amino Acids Into Azurin and Cua Azurin
    ! ! ! ! ! "#$%&'(!)*+!#$,+-!$.!/+)0,!%&'1&'(!,&(0'1-!&'!23"#+1$4&'-5! 0 &'2$#"$#0)&'(!'$'"#$)+&'$(+'&2!0/&'$!02&1-!&')$!063#&'!0'1!23 !063#&'! ! ! ! ! ! ! %7! ! 8+9&'!/:!2,0#8! ! ! ! ! ! ! ! 1&--+#)0)&$'! ! -;<=>??@A!>B!CDE?>DF!G;FG>FF=@B?!HG!?I@!E@J;>E@=@B?K! GHE!?I@!1HL?HE!HG!"I>FHKHCIM!>B!%>HLI@=>K?EM! >B!?I@!(EDA;D?@!2HFF@N@!HG!?I@! 3B>O@EK>?M!HG!&FF>BH>K!D?!3E<DBDP2ID=CD>NBQ!RSTS! ! ! ! 3E<DBDQ!&FF>BH>K! ! ! ! 1HL?HEDF!2H==>??@@5! ! ! "EHG@KKHE!7>!,;Q!2ID>E!DBA!2HP1>E@L?HE!HG!#@K@DELI! ! ! "EHG@KKHE!U>FGE@A!ODB!A@E!1HBVQ!2HP1>E@L?HE!HG!#@K@DELI! ! "EHG@KKHE!0B?HBM!2EHG?K! ! "EHG@KKHE!+E>V!WDVH<KKHB! ABSTRACT Metalloproteins play important roles in biological systems since metal-binding sites are found in ~ 1/3 of structurally characterized proteins and in ~ 1/2 of all proteins. Despite progress, the role of many metal-binding sites remains poorly understood. Furthermore, their detailed geometric and electronic structure has yet to be fully elucidated. Site-directed mutagenesis using natural amino acids has continued to be the primary method of probing of metal-binding sites. However, it has become increasingly evident that site-directed mutagenesis, though powerful, cannot address the precise role of the metal ligands without changing multiple factors because of limited number of natural amino acids that allows isostructural substitutions. The relative paucity of functional group availability within the proteinogenic amino acids also limits ability to fine tune and expand protein’s activity.
    [Show full text]
  • Eight Novel Mutations of the Androgen Receptor Gene in Patients with Androgen Insensitivity Syndrome
    J Hum Genet (2001) 46:560–565 © Jpn Soc Hum Genet and Springer-Verlag 2001 ORIGINAL ARTICLE Bertha Chávez · Juan Pablo Méndez Alfredo Ulloa-Aguirre · Fernando Larrea · Felipe Vilchis Eight novel mutations of the androgen receptor gene in patients with androgen insensitivity syndrome Received: May 7, 2001 / Accepted: June 28, 2001 Abstract Androgen insensitivity syndrome (AIS) is an Introduction X-linked genetic disorder of male sexual differentiation caused by mutations in the androgen receptor (AR) gene. A reliable genotype–phenotype correlation in these patients Androgen insensitivity syndrome (AIS) is an X-linked does not exist as yet. Here we report the molecular studies hereditary disorder that leads to male pseudohermaphro- performed on eight individuals with AIS. Exon-specific ditism with variable phenotypes. This defective response polymerase chain reaction (PCR), single-strand conforma- results from the impairment of androgen receptor (AR) tion polymorphism, and sequencing analyses, were per- function in activating androgen responsive genes in target formed in exons 2 to 8 of the AR gene. In one case, total cells (McPhaul et al. 1993). The phenotype in 46,XY af- cellular RNA was extracted from genital skin fibroblasts fected individuals varies depending on the extent of the and reverse transcriptase-PCR was performed. Six different AR defect, ranging from subjects with complete androgen point mutations leading to amino acid substitutions (P682T, insensitivity syndrome (CAIS) where a female phenotype is Q711E, G743E, F827V, H874R, D879Y), one splice- observed, to patients with genital ambiguity who present junction mutation (gÆc at ϩ5, exon 6/intron 6), and a mis- with partial androgen insensitivity syndrome (PAIS).
    [Show full text]